DK3765012T3 - Dgat1-hæmmere til anvendelse i behandling af konstipation - Google Patents
Dgat1-hæmmere til anvendelse i behandling af konstipationInfo
- Publication number
- DK3765012T3 DK3765012T3 DK19767984.8T DK19767984T DK3765012T3 DK 3765012 T3 DK3765012 T3 DK 3765012T3 DK 19767984 T DK19767984 T DK 19767984T DK 3765012 T3 DK3765012 T3 DK 3765012T3
- Authority
- DK
- Denmark
- Prior art keywords
- constipation
- treatment
- dgat1 inhibitors
- dgat1
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644033P | 2018-03-16 | 2018-03-16 | |
| PCT/US2019/022499 WO2019178492A1 (en) | 2018-03-16 | 2019-03-15 | Compositions and methods for treating severe constipation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3765012T3 true DK3765012T3 (da) | 2026-04-27 |
Family
ID=67904819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19767984.8T DK3765012T3 (da) | 2018-03-16 | 2019-03-15 | Dgat1-hæmmere til anvendelse i behandling af konstipation |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US11224590B2 (https=) |
| EP (1) | EP3765012B1 (https=) |
| JP (1) | JP7527984B2 (https=) |
| KR (1) | KR102747096B1 (https=) |
| CN (1) | CN111936137B (https=) |
| AU (1) | AU2019234956B2 (https=) |
| BR (1) | BR112020018790A2 (https=) |
| DK (1) | DK3765012T3 (https=) |
| EA (1) | EA202092190A1 (https=) |
| FI (1) | FI3765012T3 (https=) |
| IL (1) | IL277332B2 (https=) |
| MX (1) | MX2020009604A (https=) |
| MY (1) | MY205335A (https=) |
| PE (1) | PE20210158A1 (https=) |
| PH (1) | PH12020551468A1 (https=) |
| SG (1) | SG11202008971VA (https=) |
| TW (1) | TWI704917B (https=) |
| WO (1) | WO2019178492A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202092190A1 (ru) | 2018-03-16 | 2020-11-19 | Анджи Фармасьютикалз Инк. | Композиции и способы для лечения сильного запора |
| KR20220052459A (ko) | 2020-10-21 | 2022-04-28 | 주식회사 엘지에너지솔루션 | 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3225997A (en) | 1996-05-30 | 1998-01-05 | Trustees Of Columbia University In The City Of New York, The | Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof |
| ATE406448T1 (de) | 1998-06-24 | 2008-09-15 | David Gladstone Inst | Diacylglycerin o-acyltransferase |
| US20030167483A1 (en) | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
| US6344548B1 (en) | 1998-06-24 | 2002-02-05 | The Regents Of The University Of California | Diacylglycerol o-acyltransferase |
| US20030154504A1 (en) | 1998-06-24 | 2003-08-14 | Farese Robert V. | Methods and compositions for modulating carbohydrate metabolism |
| US6100077A (en) | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
| WO2002002551A1 (en) | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| US6444427B1 (en) | 2000-07-11 | 2002-09-03 | The Regents Of The University Of California | Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof |
| JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Ｄｇａｔ阻害剤 |
| RU2342388C2 (ru) | 2002-11-22 | 2008-12-27 | Джапан Тобакко Инк. | Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием |
| US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
| AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
| WO2005013907A2 (en) | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
| GB0325192D0 (en) | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
| JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
| AU2005209115A1 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
| JP2006045209A (ja) | 2004-07-02 | 2006-02-16 | Sankyo Co Ltd | ウレア誘導体 |
| WO2006004200A1 (ja) | 2004-07-02 | 2006-01-12 | Sankyo Company, Limited | ウレア誘導体 |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| WO2006044775A2 (en) | 2004-10-15 | 2006-04-27 | Bayer Pharmaceuticals Corporation | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
| BRPI0519058A2 (pt) | 2004-12-14 | 2008-12-23 | Astrazeneca Ab | composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto |
| WO2006113919A2 (en) | 2005-04-19 | 2006-10-26 | Bayer Pharmaceuticals Corporation | Aryl alkyl acid derivatives for and use thereof |
| WO2007002740A2 (en) | 2005-06-28 | 2007-01-04 | E. I. Du Pont De Nemours And Company | Buffer compositions |
| EP2418202B1 (en) * | 2006-03-31 | 2014-01-29 | Novartis AG | (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors |
| GB0611506D0 (en) | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| JO2972B1 (en) * | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
| AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| WO2009112445A1 (en) * | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| US8324241B2 (en) | 2008-04-11 | 2012-12-04 | Bristol-Myers Squibb Company | Triazolo compounds useful as DGAT1 inhibitors |
| NZ602125A (en) * | 2010-03-30 | 2014-01-31 | Novartis Ag | Uses of dgat1 inhibitors |
| CN102869645A (zh) * | 2010-04-08 | 2013-01-09 | 美迪诺亚公司 | 用于治疗肠易激综合征的方法和组合物 |
| AR083417A1 (es) * | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| WO2013130370A2 (en) | 2012-03-01 | 2013-09-06 | Merck Sharp & Dohme Corp. | Compounds as dgat-1 inhibitors |
| WO2013169648A1 (en) * | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
| MX2015002210A (es) * | 2012-08-29 | 2015-05-08 | Salix Pharmaceuticals Inc | Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas. |
| BR112016015851A2 (pt) * | 2014-01-09 | 2017-08-08 | Sanofi Sa | Formulações farmacêuticas estabilizadas de insulina aspart |
| EA202092190A1 (ru) | 2018-03-16 | 2020-11-19 | Анджи Фармасьютикалз Инк. | Композиции и способы для лечения сильного запора |
-
2019
- 2019-03-15 EA EA202092190A patent/EA202092190A1/ru unknown
- 2019-03-15 KR KR1020207029661A patent/KR102747096B1/ko active Active
- 2019-03-15 FI FIEP19767984.8T patent/FI3765012T3/fi active
- 2019-03-15 CN CN201980019537.3A patent/CN111936137B/zh active Active
- 2019-03-15 BR BR112020018790-9A patent/BR112020018790A2/pt active Search and Examination
- 2019-03-15 JP JP2020573085A patent/JP7527984B2/ja active Active
- 2019-03-15 WO PCT/US2019/022499 patent/WO2019178492A1/en not_active Ceased
- 2019-03-15 DK DK19767984.8T patent/DK3765012T3/da active
- 2019-03-15 AU AU2019234956A patent/AU2019234956B2/en active Active
- 2019-03-15 US US16/355,085 patent/US11224590B2/en active Active
- 2019-03-15 EP EP19767984.8A patent/EP3765012B1/en active Active
- 2019-03-15 SG SG11202008971VA patent/SG11202008971VA/en unknown
- 2019-03-15 IL IL277332A patent/IL277332B2/en unknown
- 2019-03-15 MY MYPI2020004779A patent/MY205335A/en unknown
- 2019-03-15 PE PE2020001407A patent/PE20210158A1/es unknown
- 2019-03-15 MX MX2020009604A patent/MX2020009604A/es unknown
- 2019-03-18 TW TW108109164A patent/TWI704917B/zh active
-
2020
- 2020-09-14 PH PH12020551468A patent/PH12020551468A1/en unknown
-
2021
- 2021-12-30 US US17/565,584 patent/US11819495B2/en active Active
-
2023
- 2023-10-11 US US18/378,976 patent/US12343334B2/en active Active
-
2025
- 2025-06-10 US US19/233,154 patent/US20260000651A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4303583T3 (da) | Csf1r-inhibitorer til anvendelse til behandling af tenosynoviale kæmpecelletumorer | |
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| HUS2500039I1 (hu) | Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| IL263484A (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| IL256056A (en) | Ezh2 inhibitors for treating lymphoma | |
| IL261721A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3368069T3 (da) | Anvendelse af myostatininhibitorer og kombinationsterapier | |
| PL3500564T3 (pl) | Inhibitory acylotransferazy diacyloglicerolu 2 | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| DK3806898T3 (da) | Gremlin-1-antagonist til anvendelse i behandling af cancer | |
| HRP20251598T1 (hr) | Mavakamten za uporabu u liječenju hipertrofične kardiomiopatije | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3185868T3 (da) | Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme | |
| DK3704108T3 (da) | Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3307296T3 (da) | Timp2 til anvendelse til behandling af aldringsassocierede tilstande | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| EP3609882A4 (en) | Heterocyclic inhibitors of pcsk9 | |
| DK3962601T3 (da) | 5-HT2A-agonister til anvendelse til behandling af depression |